-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LQ6vrZ30Z4QudtgtdKPbhOUbywrqZK2WjLHU4YolCCcMXJKq+PC+ydz3gjk+yqYm WCZGOlXCgCWaG3WKQcUQYQ== 0001002014-04-000143.txt : 20040330 0001002014-04-000143.hdr.sgml : 20040330 20040330124756 ACCESSION NUMBER: 0001002014-04-000143 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20031231 FILED AS OF DATE: 20040330 EFFECTIVENESS DATE: 20040330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHAGE GENOMICS INC CENTRAL INDEX KEY: 0001084226 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 980232244 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30995 FILM NUMBER: 04699278 BUSINESS ADDRESS: STREET 1: 4861 CAMBRIDGE STREET STREET 2: - CITY: BURNABY STATE: A1 ZIP: V5C 1H9 BUSINESS PHONE: (604) 622-6209 MAIL ADDRESS: STREET 1: SAME AS ABOVE FORMER COMPANY: FORMER CONFORMED NAME: REGMA BIO TECHNOLOGIES LTD DATE OF NAME CHANGE: 20020221 FORMER COMPANY: FORMER CONFORMED NAME: LCM EQUITY INC DATE OF NAME CHANGE: 20000711 NT 10-K 1 pgi12b25.htm PHAGE GENOMICS, INC. FORM 12B-25 FOR THE FILING PERIOD DECEMBER 31, 2003 Phage Genomics, Inc. Form 12B-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25

NOTIFICATION OF LATE FILING

[X]

Form 10-K

[   ]

Form 20-F

[   ]

Form 11-K

[   ]

Form 10-Q

For the period ended December 31, 2003.

[   ]
[   ]
[   ]
[   ]

Transition Report on Form 10-K.
Transition Report on Form 20-F.
Transition Report on Form 11-K.
Transition Report on Form 10-Q.

 

For the Transition Period Ended:

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

PHAGE GENOMICS, INC.
 Full Name of Registrant

File No. 000-30995

4861 Cambridge Street
Burnaby, British Columbia
Canada V5C 1H9
 Address of principal executive office, including zip.

PART II - RULES 12B-25 and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25, the following should be completed.

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[x]

(b)

The subject annual report, semi-annual report, transition report of Form 10-Q, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

PART III - NARRATIVE

Auditors were unable to complete their review of the unaudited financial statements.

PART IV - OTHER INFORMATION
  1. Name and telephone number of person to contact in regard to this notification.

    Graham Hughes
    4861 Cambridge Street
    Burnaby, British Columbia
    Canada V5C 1H9
    (604) 622-6209
  2. Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify reports.

    Yes

    [ x]

    No

    [   ]

  3. Is its anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    Yes

    [   ]

    No

    [ x ]

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

PHAGE GENOMICS, INC. has caused this notification to signed on its behalf by the undersigned hereunto duly authorized, on this 30th day of March, 2004.

 

PHAGE GENOMICS, INC.
formerly Regma Bio Technologies Limited
 (Registrant)

BY:

/s/ Graham Hughes

 

Graham Hughes
President, Chief Executive Officer and a member of the Board of Directors

 

 

 

- 2 -

 -----END PRIVACY-ENHANCED MESSAGE-----